244 related articles for article (PubMed ID: 21907198)
1. Trials for the co-expression of the merozoite surface protein-1 and circumsporozoite protein genes of Plasmodium vivax.
Lee C; Chung KW; Kim TS; Choi KM; Choi YK; Chung NJ; Rhie HG; Lee HS; Lee SJ; Lee HW
Exp Parasitol; 2011 Nov; 129(3):227-33. PubMed ID: 21907198
[TBL] [Abstract][Full Text] [Related]
2. Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus.
Lee C; Kim HH; Choi KM; Chung KW; Choi YK; Jang MJ; Kim TS; Chung NJ; Rhie HG; Lee HS; Sohn Y; Kim H; Lee SJ; Lee HW
Malar J; 2011 Apr; 10():106. PubMed ID: 21529346
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and immunological characterization of E. coli expressed 42 kDa fragment of Plasmodium vivax and P. cynomolgi bastianelli merozoite surface protein-1.
Kaushal DC; Kaushal NA; Narula A; Kumar N; Puri SK; Dutta S; Lanar DE
Indian J Biochem Biophys; 2007 Dec; 44(6):429-36. PubMed ID: 18320841
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium vivax: comparison of the immune responses between oral and parenteral immunization of rPv54 in BALB/c mice.
Kwon MH; Kim HH; Lee HS; Kim TS; Oh CM; Ahn YJ; Hwang SK; Sohn Y; Kim H; Lee HW
Exp Parasitol; 2010 Oct; 126(2):217-23. PubMed ID: 20460123
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
6. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
Mehrizi AA; Zakeri S; Rafati S; Salmanian AH; Djadid ND
Parasite Immunol; 2011 Nov; 33(11):594-608. PubMed ID: 21883290
[TBL] [Abstract][Full Text] [Related]
7. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.
Yadava A; Sattabongkot J; Washington MA; Ware LA; Majam V; Zheng H; Kumar S; Ockenhouse CF
Infect Immun; 2007 Mar; 75(3):1177-85. PubMed ID: 17158893
[TBL] [Abstract][Full Text] [Related]
8. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1
Rocha MV; Françoso KS; Lima LC; Camargo TM; Machado RLD; Costa FTM; Rénia L; Nosten F; Russell B; Rodrigues MM; Soares IS
Vaccine; 2017 Apr; 35(18):2463-2472. PubMed ID: 28341111
[TBL] [Abstract][Full Text] [Related]
9. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1.
Rodrigues MH; Rodrigues KM; Oliveira TR; Cômodo AN; Rodrigues MM; Kocken CH; Thomas AW; Soares IS
Int J Parasitol; 2005 Feb; 35(2):185-92. PubMed ID: 15710439
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
[TBL] [Abstract][Full Text] [Related]
11. Cloning, overexpression and characterization of soluble 42kDa fragment of merozoite surface protein-1 of Plasmodium vivax.
Sheikh IH; Kaushal DC; Singh V; Kumar N; Chandra D; Kaushal NA
Protein Expr Purif; 2014 Nov; 103():64-74. PubMed ID: 25195175
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of Plasmodium vivax merozoite surface protein-9 recombinant proteins expressed in E. coli.
Oliveira-Ferreira J; Vargas-Serrato E; Barnwell JW; Moreno A; Galinski MR
Vaccine; 2004 May; 22(15-16):2023-30. PubMed ID: 15121316
[TBL] [Abstract][Full Text] [Related]
13. Biological, immunological and functional properties of two novel multi-variant chimeric recombinant proteins of CSP antigens for vaccine development against Plasmodium vivax infection.
Shabani SH; Zakeri S; Salmanian AH; Amani J; Mehrizi AA; Snounou G; Nosten F; Andolina C; Mourtazavi Y; Djadid ND
Mol Immunol; 2017 Oct; 90():158-171. PubMed ID: 28800475
[TBL] [Abstract][Full Text] [Related]
14. Direct effect of Plasmodium vivax recombinant vaccine candidates AMA-1 and MSP-119 on the innate immune response.
Bueno LL; Fujiwara RT; Soares IS; Braga EM
Vaccine; 2008 Feb; 26(9):1204-13. PubMed ID: 18242795
[TBL] [Abstract][Full Text] [Related]
15. A direct sandwich ELISA to detect antibodies against the C-terminal region of merozoite surface protein 1 could be a useful diagnostic method to identify Plasmodium vivax exposed persons.
Lim KJ; Park JW; Sohn MJ; Lee S; Oh JH; Kim HC; Bahk YY; Kim YS
Parasitol Res; 2002 Sep; 88(9):855-60. PubMed ID: 12172819
[TBL] [Abstract][Full Text] [Related]
16. Soluble recombinant merozoite surface antigen-142kDa of Plasmodium vivax: An improved diagnostic antigen for vivax malaria.
Mirahmadi H; Fallahi S; Seyyed Tabaei SJ
J Microbiol Methods; 2016 Apr; 123():44-50. PubMed ID: 26851675
[TBL] [Abstract][Full Text] [Related]
17. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.
Bargieri DY; Rosa DS; Braga CJ; Carvalho BO; Costa FT; Espíndola NM; Vaz AJ; Soares IS; Ferreira LC; Rodrigues MM
Vaccine; 2008 Nov; 26(48):6132-42. PubMed ID: 18804504
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
19. High frequency of genetic diversity of Plasmodium vivax field isolates in Myanmar.
Moon SU; Lee HW; Kim JY; Na BK; Cho SH; Lin K; Sohn WM; Kim TS
Acta Trop; 2009 Jan; 109(1):30-6. PubMed ID: 18851938
[TBL] [Abstract][Full Text] [Related]
20. High immunogenecity and erythrocyte-binding activity in the tryptophan-rich domain (TRD) of the 74-kDa Plasmodium vivax alanine-tryptophan-rich antigen (PvATRAg74).
Alam MT; Bora H; Singh N; Sharma YD
Vaccine; 2008 Jul; 26(31):3787-94. PubMed ID: 18579264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
